The finding in the aforementioned title was presented at the 43rd annual conference of the European Study of Diabetes. The meeting was held in Amsterdam, in the Netherlands. Type 2 diabetes patients who did not achieve their glycemic targets even though they were taking high doses of metformin were given galvus in addition to their metformin treatment. They were found to be four more times liable to reach the recommended goal.
At that time, this drug was projected to receive approval in Europe for marketing purposes. For awhile I wondered whatever happened to it. This is what I found: EU approved Novartis combo drug eucreas as reported in February 2008. The regulators had given the green light to the new combination diabetes drug called eucreas. This contains the inhibitor galvus that was recently approved.
The approval came after Novartis proposed changes to the label. It recommended that liver monitoring should be in place at the beginning of the treatment, and should be conducted every three months for the first year and every so often after this period
The approval was given the go-ahead after the European approval of the galvus that was updated. It will be designated for use with metformin or any of the sulphonylureas. The new European Guidelines for Diabetes says that polypharmacy is the best development in the cure of diabetes.
The combination of drugs is meant to make the treatment more efficient and at the same time lessen the side effects. The European guideline recommends an HbA1c goal of 6.5% while the American Diabetes Association suggests a target of 7%. This is the goal of many approaches on how is diabetes treated.
A principal medical officer at Novartis, USA, Dr. Sylvia Dejager and her colleagues examined the effects of galvus as a monotheraphy and in combination with metformin. They presented their findings at the meeting in the Netherlands saying that when combined with metformin four times more patients achieved the A1c level of 7%.
No comments:
Post a Comment